Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,870 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Substance Use Disorders, HIV
Interventions: PrEP navigation + text messaging, Standard of Care, Contingency Management; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: electronic medical record, Integrated Approach to Care, usual care, Shared Decision Making, school based care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 1,040 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Charlotte, North Carolina

Conditions: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
Interventions: Exercise, Cardiopulmonary Exercise Test (CPET); Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cerebral Blood Flow, APOE 4
Interventions: FMD1 (LNT22-017-1), Rapamycin, Placebo; Dietary Supplement · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke Code, Large Vessel Occlusion, Acute Ischemic Stroke
Interventions: Point of Care Rapid Assay; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Years to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Myeloma
Interventions: Fludarabine monophosphate, melphalan, Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 69 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Hematopoietic Stem Cell Transplantation, Graft Failure
Interventions: Emapalumab 3 mg/kg, Emapalumab 10 mg/kg; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Posttraumatic Stress Disorder, Tinnitus
Interventions: resting-state functional MRI, Clinician Administered PTSD Scale for the DSM-5 (CAPS-5), Tympanometry, Tinnitus Assessment, Otoscopy, Pure tone air and bone-conduction, Speech testing, Loudness Discomfort, Quick Speech in Noise Test, Distortion-Product Otoacoustic Emissions (DPOAE); Diagnostic Test
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Achalasia
Interventions: Barostat; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Transplant Rejection
Interventions: Forceps Biopsy, Cryoprobe Biopsy; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ofatumumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Osteonecrosis
Interventions: Functional Mobility Assessment, GAITRite® System, Range of Motion; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 29 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetes Mellitus
Interventions: Insulin, Isophane, insulin glargine; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
Interventions: EBV-specific T cells: A, EBV-specific T cells: B; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: PreDiabetes
Interventions: Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Volunteers
Interventions: AMG 378, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lake Forest, California • Overland Park, Kansas

Conditions: Stroke, Dysphagia
Interventions: Tongue Pressure Resistance Training; Behavioral
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Wheaton, Illinois

Conditions: Healthy Participants
Interventions: PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Diffuse Large B Cell Lymphoma
Interventions: 18F-FluorApoTrace; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ischemic Stroke
Interventions: Posturography, Walking Speed, Instrumented 7M Timed UP and GO, Fall Event Records, MRI (3T); Diagnostic Test · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

ASK-PrEP (Assistance Services Knowledge-PrEP)

Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN

Active Surveillance Exercise Clinical Trial

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

Evaluation of a Point-of-care Lateral Flow Assay in Glial Fibrillary Acidic Protein (GFAP) and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Neurobiological Similarities of Tinnitus and PTSD

Sensorimotor Dysfunction in Achalasia

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Mechanisms for Activation of Beige Adipose Tissue in Humans

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Tongue Pressure Resistance Training for Swallowing Impairment Post-Stroke

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Imaging Apoptosis for Lymphoma Treatment Response

Post-Stroke Sensory Reweighting on Walking and Balance Outcomes